You are here

Report: Market for Pancreatic Cancer Therapies Expected to Double to $1.3 Billion Over Next Decade

Growth fueled by three new agents (May 7)

Decision Resources, a research and advisory firm located in Burlington, Mass., finds that the pancreatic cancer therapy market will nearly double to $1.3 billion in 2022, owing to the launch and rapid uptake of three high-priced agents — Abraxane (paclitaxel, Celgene/Taiho); Estybon (rigosertib, Onconova Therapeutics/Baxter International/SymBio Pharmaceuticals); and MM-398 (Merrimack Pharmaceuticals), a novel formulation of irinotecan. Even though these agents do not substantially improve the overall survival of pancreatic cancer patients, they will have a significant effect on current treatment, the company says.

The report also finds that a significant commercial reward awaits developers of therapies that are more effective and better tolerated than the FOLFIRINOX regimen (folic acid [leucovorin calcium], fluorouracil, irinotecan hydrochloride, and oxaliplatin) in this disease, as the need for efficacious, well-tolerated therapies will remain through 2022.

“There is a dire need for novel therapies to, at a minimum, match FOLFIRINOX’s efficacy,” said analyst Orestis Mavroudis-Chocholis, PhD. “FOLFIRINOX is reserved for young, fitter patients, who are better able to tolerate it, and is therefore prescribed only to a minority of pancreatic cancer patients who typically have rapidly progressing disease and declining performance status. Even an agent with equal efficacy but a better safety profile will quickly become the standard of care in pancreatic cancer.”

The report also finds that surveyed physicians are excited by the prospect of stromal over-expression of secreted protein rich in cysteine (SPARC) as a predictive biomarker for a response to Abraxane and hope that this could herald the start of a personalized approach to the treatment of pancreatic cancer.

Source: Decision Resources; May 7, 2013.

More Headlines

Disease Occurs in 1 in 5,000 Male Births in the U.S.
Non-Invasive Therapy for Patients Who are Nonresponsive to Antidepressants
Vials Being Rationed, Only One Manufacturer
Several Health Insurers Now Consider DBS Therapy for Epilepsy a Covered Indication
Drug Has Potential Role In Oxidative Stress, Inflammation, and Neurodegeneration
OCA Meets Primary Endpoint of Improvement in Liver Fibrosis
Scan Could Improve Understanding of Dopamine Function in Schizophrenia
Liver Fluke Infestation Affects Almost 2.5 Million People Globally